ID   PLK4_HUMAN              Reviewed;         970 AA.
AC   O00444; B2RAL0; B7Z837; B7Z8G7; Q8IYF0; Q96Q95; Q9UD84; Q9UDE2;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2007, sequence version 3.
DT   12-OCT-2022, entry version 196.
DE   RecName: Full=Serine/threonine-protein kinase PLK4 {ECO:0000305};
DE            EC=2.7.11.21 {ECO:0000269|PubMed:16244668, ECO:0000269|PubMed:18239451, ECO:0000269|PubMed:19164942};
DE   AltName: Full=Polo-like kinase 4;
DE            Short=PLK-4;
DE   AltName: Full=Serine/threonine-protein kinase 18;
DE   AltName: Full=Serine/threonine-protein kinase Sak;
GN   Name=PLK4 {ECO:0000312|HGNC:HGNC:11397}; Synonyms=SAK, STK18;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS THR-232 AND ASP-830.
RC   TISSUE=Lung;
RA   Karn T., Holtrich U., Wolf G., Hock B., Strebhardt K.,
RA   Ruebsamen-Waigmann H.;
RT   "Human SAK related to the PLK/polo family of cell cycle kinases shows high
RT   mRNA expression in testis.";
RL   Oncol. Rep. 4:505-510(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION BY TEC, AND
RP   VARIANTS THR-232 AND ASP-830.
RC   TISSUE=Blood;
RX   PubMed=11489907; DOI=10.1074/jbc.m106249200;
RA   Yamashita Y., Kajigaya S., Yoshida K., Ueno S., Ota J., Ohmine K., Ueda M.,
RA   Miyazato A., Ohya K., Kitamura T., Ozawa K., Mano H.;
RT   "Sak serine-threonine kinase acts as an effector of Tec tyrosine kinase.";
RL   J. Biol. Chem. 276:39012-39020(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANTS
RP   THR-232 AND ASP-830.
RC   TISSUE=Testis, and Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 134-196.
RX   PubMed=8260651; DOI=10.1006/smim.1993.1041;
RA   Mills G.B., Schmandt R., Gibson S., Leung B., Hill M., May C., Shi Y.F.,
RA   Branch D.R., Radvanyi L., Truitt K.E., Imboden J.;
RT   "Transmembrane signaling by the interleukin-2 receptor: progress and
RT   conundrums.";
RL   Semin. Immunol. 5:345-364(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 135-196.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=1311287; DOI=10.1002/ijc.2910500419;
RA   Lehtola L., Partanen J., Sistonen L., Korhonen J., Warri A., Harkonen P.,
RA   Clarke R., Alitalo K.;
RT   "Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs
RT   expressed in MCF-7 breast-cancer cells.";
RL   Int. J. Cancer 50:598-603(1992).
RN   [7]
RP   FUNCTION.
RX   PubMed=16326102; DOI=10.1016/j.cub.2005.11.042;
RA   Bettencourt-Dias M., Rodrigues-Martins A., Carpenter L., Riparbelli M.,
RA   Lehmann L., Gatt M.K., Carmo N., Balloux F., Callaini G., Glover D.M.;
RT   "SAK/PLK4 is required for centriole duplication and flagella development.";
RL   Curr. Biol. 15:2199-2207(2005).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ASP-154.
RX   PubMed=16244668; DOI=10.1038/ncb1320;
RA   Habedanck R., Stierhof Y.-D., Wilkinson C.J., Nigg E.A.;
RT   "The Polo kinase Plk4 functions in centriole duplication.";
RL   Nat. Cell Biol. 7:1140-1146(2005).
RN   [9]
RP   INDUCTION BY TP53.
RX   PubMed=15967108; DOI=10.1593/neo.04325;
RA   Li J., Tan M., Li L., Pamarthy D., Lawrence T.S., Sun Y.;
RT   "SAK, a new polo-like kinase, is transcriptionally repressed by p53 and
RT   induces apoptosis upon RNAi silencing.";
RL   Neoplasia 7:312-323(2005).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17681131; DOI=10.1016/j.devcel.2007.07.002;
RA   Kleylein-Sohn J., Westendorf J., Le Clech M., Habedanck R., Stierhof Y.-D.,
RA   Nigg E.A.;
RT   "Plk4-induced centriole biogenesis in human cells.";
RL   Dev. Cell 13:190-202(2007).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-41 AND THR-170.
RX   PubMed=18239451; DOI=10.4161/cc.7.4.5387;
RA   Bonni S., Ganuelas M.L., Petrinac S., Hudson J.W.;
RT   "Human Plk4 phosphorylates Cdc25C.";
RL   Cell Cycle 7:545-547(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-401, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-41 AND THR-170.
RX   PubMed=19164942; DOI=10.4161/cc.8.2.7355;
RA   Petrinac S., Ganuelas M.L., Bonni S., Nantais J., Hudson J.W.;
RT   "Polo-like kinase 4 phosphorylates Chk2.";
RL   Cell Cycle 8:327-329(2009).
RN   [15]
RP   INDUCTION.
RX   PubMed=19454482; DOI=10.1242/jcs.036715;
RA   Kuriyama R., Bettencourt-Dias M., Hoffmann I., Arnold M., Sandvig L.;
RT   "Gamma-tubulin-containing abnormal centrioles are induced by insufficient
RT   Plk4 in human HCT116 colorectal cancer cells.";
RL   J. Cell Sci. 122:2014-2023(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-401 AND SER-817, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   INTERACTION WITH CEP152.
RX   PubMed=21059844; DOI=10.1083/jcb.201007107;
RA   Cizmecioglu O., Arnold M., Bahtz R., Settele F., Ehret L.,
RA   Haselmann-Weiss U., Antony C., Hoffmann I.;
RT   "Cep152 acts as a scaffold for recruitment of Plk4 and CPAP to the
RT   centrosome.";
RL   J. Cell Biol. 191:731-739(2010).
RN   [18]
RP   INTERACTION WITH CEP152.
RX   PubMed=20852615; DOI=10.1038/nature09445;
RA   Dzhindzhev N.S., Yu Q.D., Weiskopf K., Tzolovsky G., Cunha-Ferreira I.,
RA   Riparbelli M., Rodrigues-Martins A., Bettencourt-Dias M., Callaini G.,
RA   Glover D.M.;
RT   "Asterless is a scaffold for the onset of centriole assembly.";
RL   Nature 467:714-718(2010).
RN   [19]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22020124; DOI=10.1038/emboj.2011.378;
RA   Tang C.J., Lin S.Y., Hsu W.B., Lin Y.N., Wu C.T., Lin Y.C., Chang C.W.,
RA   Wu K.S., Tang T.K.;
RT   "The human microcephaly protein STIL interacts with CPAP and is required
RT   for procentriole formation.";
RL   EMBO J. 30:4790-4804(2011).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF FBXW5.
RX   PubMed=21725316; DOI=10.1038/ncb2282;
RA   Puklowski A., Homsi Y., Keller D., May M., Chauhan S., Kossatz U.,
RA   Grunwald V., Kubicka S., Pich A., Manns M.P., Hoffmann I., Gonczy P.,
RA   Malek N.P.;
RT   "The SCF-FBXW5 E3-ubiquitin ligase is regulated by PLK4 and targets HsSAS-6
RT   to control centrosome duplication.";
RL   Nat. Cell Biol. 13:1004-1009(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-665, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INVOLVEMENT IN MCPHCR.
RX   PubMed=25344692; DOI=10.1038/ng.3122;
RA   Martin C.A., Ahmad I., Klingseisen A., Hussain M.S., Bicknell L.S.,
RA   Leitch A., Nuernberg G., Toliat M.R., Murray J.E., Hunt D., Khan F.,
RA   Ali Z., Tinschert S., Ding J., Keith C., Harley M.E., Heyn P., Mueller R.,
RA   Hoffmann I., Daire V.C., Dollfus H., Dupuis L., Bashamboo A.,
RA   McElreavey K., Kariminejad A., Mendoza-Londono R., Moore A.T., Saggar A.,
RA   Schlechter C., Weleber R., Thiele H., Altmueller J., Hoehne W.,
RA   Hurles M.E., Noegel A.A., Baig S.M., Nuernberg P., Jackson A.P.;
RT   "Mutations in PLK4, encoding a master regulator of centriole biogenesis,
RT   cause microcephaly, growth failure and retinopathy.";
RL   Nat. Genet. 46:1283-1292(2014).
RN   [23]
RP   INTERACTION WITH CEP78, AND SUBCELLULAR LOCATION.
RX   PubMed=27246242; DOI=10.1242/jcs.184093;
RA   Brunk K., Zhu M., Baerenz F., Kratz A.S., Haselmann-Weiss U., Antony C.,
RA   Hoffmann I.;
RT   "Cep78 is a new centriolar protein involved in Plk4-induced centriole
RT   overduplication.";
RL   J. Cell Sci. 129:2713-2718(2016).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND ACETYLATION AT LYS-45 AND LYS-46.
RX   PubMed=27796307; DOI=10.1038/ncomms13227;
RA   Fournier M., Orpinell M., Grauffel C., Scheer E., Garnier J.M., Ye T.,
RA   Chavant V., Joint M., Esashi F., Dejaegere A., Goenczy P., Tora L.;
RT   "KAT2A/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in
RT   preventing centrosome amplification.";
RL   Nat. Commun. 7:13227-13227(2016).
RN   [25]
RP   FUNCTION, INTERACTION WITH CEP131, AND SUBCELLULAR LOCATION.
RX   PubMed=30804208; DOI=10.1074/jbc.ra118.004867;
RA   Denu R.A., Sass M.M., Johnson J.M., Potts G.K., Choudhary A., Coon J.J.,
RA   Burkard M.E.;
RT   "Polo-like kinase 4 maintains centriolar satellite integrity by
RT   phosphorylation of centrosomal protein 131 (CEP131).";
RL   J. Biol. Chem. 294:6531-6549(2019).
RN   [26] {ECO:0007744|PDB:6W38, ECO:0007744|PDB:6W3I, ECO:0007744|PDB:6W3J}
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 585-807 IN COMPLEXES WITH TENT5C
RP   AND CEP192, INTERACTION WITH TENT5C, MUTAGENESIS OF ASN-669 AND ILE-670,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=32433990; DOI=10.1016/j.str.2020.04.023;
RA   Chen H., Lu D., Shang G., Gao G., Zhang X.;
RT   "Structural and Functional Analyses of the FAM46C/Plk4 Complex.";
RL   Structure 28:910-921.e4(2020).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 2-275.
RG   New York structural genomix research consortium (NYSGXRC);
RT   "Crystal structure of PLK4 kinase.";
RL   Submitted (JUN-2009) to the PDB data bank.
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-86; HIS-146; THR-226; THR-232; LEU-317;
RP   ASP-449; SER-519 AND ASP-830.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that plays a central role in
CC       centriole duplication. Able to trigger procentriole formation on the
CC       surface of the parental centriole cylinder, leading to the recruitment
CC       of centriole biogenesis proteins such as SASS6, CENPJ/CPAP, CCP110,
CC       CEP135 and gamma-tubulin. When overexpressed, it is able to induce
CC       centrosome amplification through the simultaneous generation of
CC       multiple procentrioles adjoining each parental centriole during S
CC       phase. Phosphorylates 'Ser-151' of FBXW5 during the G1/S transition,
CC       leading to inhibit FBXW5 ability to ubiquitinate SASS6. Its central
CC       role in centriole replication suggests a possible role in
CC       tumorigenesis, centrosome aberrations being frequently observed in
CC       tumors. Also involved in deuterosome-mediated centriole amplification
CC       in multiciliated that can generate more than 100 centrioles. Also
CC       involved in trophoblast differentiation by phosphorylating HAND1,
CC       leading to disrupt the interaction between HAND1 and MDFIC and activate
CC       HAND1. Phosphorylates CDC25C and CHEK2. Required for the recruitment of
CC       STIL to the centriole and for STIL-mediated centriole amplification
CC       (PubMed:22020124). Phosphorylates CEP131 at 'Ser-78' and PCM1 at 'Ser-
CC       372' which is essential for proper organization and integrity of
CC       centriolar satellites (PubMed:30804208). {ECO:0000269|PubMed:16244668,
CC       ECO:0000269|PubMed:16326102, ECO:0000269|PubMed:17681131,
CC       ECO:0000269|PubMed:18239451, ECO:0000269|PubMed:19164942,
CC       ECO:0000269|PubMed:21725316, ECO:0000269|PubMed:22020124,
CC       ECO:0000269|PubMed:27796307, ECO:0000269|PubMed:30804208}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.21;
CC         Evidence={ECO:0000269|PubMed:16244668, ECO:0000269|PubMed:18239451,
CC         ECO:0000269|PubMed:19164942};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.21; Evidence={ECO:0000269|PubMed:16244668,
CC         ECO:0000269|PubMed:18239451, ECO:0000269|PubMed:19164942};
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with CEP152 (via N-
CC       terminus). Interacts with CEP78; this interaction may be important for
CC       proper PLK4 localization to the centriole and PLK4-induced
CC       overduplication of centrioles (PubMed:27246242). Interacts with CEP131
CC       (PubMed:30804208). Interacts simultaneously with TENT5C and CEP192
CC       (PubMed:32433990). Interacts with TENT5C; this interaction leads to the
CC       TENT5C recruitment in the centrosome (PubMed:32433990).
CC       {ECO:0000250|UniProtKB:Q64702, ECO:0000269|PubMed:20852615,
CC       ECO:0000269|PubMed:21059844, ECO:0000269|PubMed:27246242,
CC       ECO:0000269|PubMed:30804208, ECO:0000269|PubMed:32433990}.
CC   -!- INTERACTION:
CC       O00444; P36575: ARR3; NbExp=3; IntAct=EBI-746202, EBI-718116;
CC       O00444; Q9Y297: BTRC; NbExp=4; IntAct=EBI-746202, EBI-307461;
CC       O00444; Q9NX04: C1orf109; NbExp=3; IntAct=EBI-746202, EBI-8643161;
CC       O00444; O94986: CEP152; NbExp=7; IntAct=EBI-746202, EBI-311012;
CC       O00444; O94986-3: CEP152; NbExp=16; IntAct=EBI-746202, EBI-15878364;
CC       O00444; Q8TEP8: CEP192; NbExp=2; IntAct=EBI-746202, EBI-2339778;
CC       O00444; Q8TEP8-3: CEP192; NbExp=13; IntAct=EBI-746202, EBI-16111881;
CC       O00444; P59910: DNAJB13; NbExp=3; IntAct=EBI-746202, EBI-11514233;
CC       O00444; Q9H8V3: ECT2; NbExp=3; IntAct=EBI-746202, EBI-1054039;
CC       O00444; Q14241: ELOA; NbExp=6; IntAct=EBI-746202, EBI-742350;
CC       O00444; O95995: GAS8; NbExp=3; IntAct=EBI-746202, EBI-1052570;
CC       O00444; Q9H4L5: OSBPL3; NbExp=3; IntAct=EBI-746202, EBI-1051317;
CC       O00444; P07237: P4HB; NbExp=3; IntAct=EBI-746202, EBI-395883;
CC       O00444; O00444: PLK4; NbExp=10; IntAct=EBI-746202, EBI-746202;
CC       O00444; P31947: SFN; NbExp=2; IntAct=EBI-746202, EBI-476295;
CC       O00444; Q96R06: SPAG5; NbExp=3; IntAct=EBI-746202, EBI-413317;
CC       O00444; Q15468: STIL; NbExp=11; IntAct=EBI-746202, EBI-7488405;
CC       O00444; Q96A09: TENT5B; NbExp=3; IntAct=EBI-746202, EBI-752030;
CC       O00444; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-746202, EBI-1105213;
CC       O00444; Q9BYV2: TRIM54; NbExp=3; IntAct=EBI-746202, EBI-2130429;
CC       O00444; O15060: ZBTB39; NbExp=3; IntAct=EBI-746202, EBI-9995672;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome, centriole {ECO:0000269|PubMed:22020124,
CC       ECO:0000269|PubMed:27246242, ECO:0000269|PubMed:27796307}. Nucleus,
CC       nucleolus {ECO:0000250|UniProtKB:Q64702}. Cleavage furrow
CC       {ECO:0000250|UniProtKB:Q64702}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:30804208,
CC       ECO:0000269|PubMed:32433990}. Note=Component of the deuterosome, a
CC       structure that promotes de novo centriole amplification in
CC       multiciliated cells that can generate more than 100 centrioles.
CC       Associates with centrioles throughout the cell cycle. According to
CC       PubMed:16244668, it is not present at cleavage furrows.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O00444-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00444-2; Sequence=VSP_038117;
CC       Name=3;
CC         IsoId=O00444-3; Sequence=VSP_038116;
CC   -!- INDUCTION: Down-regulated in HCT 116 colorectal cancer cells, leading
CC       to aberrant centrioles composed of disorganized cylindrical
CC       microtubules and displaced appendages. Down-regulated by p53/TP53.
CC       {ECO:0000269|PubMed:15967108, ECO:0000269|PubMed:19454482}.
CC   -!- DOMAIN: Cryptic POLO box 1 (CPB1) and Cryptic POLO box 2 (CPB2) domains
CC       can simultaneously bind to both TENT5C and CEP192.
CC       {ECO:0000269|PubMed:32433990}.
CC   -!- PTM: Acetylation by KAT2A and KAT2B impairs kinase activity by shifting
CC       the kinase to an inactive conformation. {ECO:0000269|PubMed:27796307}.
CC   -!- PTM: Ubiquitinated; leading to its degradation by the proteasome.
CC       {ECO:0000250}.
CC   -!- PTM: Tyrosine-phosphorylated by TEC. {ECO:0000269|PubMed:11489907}.
CC   -!- DISEASE: Microcephaly and chorioretinopathy, autosomal recessive, 2
CC       (MCCRP2) [MIM:616171]: A severe disorder characterized by microcephaly,
CC       delayed psychomotor development, growth retardation with dwarfism, and
CC       ocular abnormalities. {ECO:0000269|PubMed:25344692}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. CDC5/Polo subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159, ECO:0000255|PROSITE-ProRule:PRU01328,
CC       ECO:0000255|PROSITE-ProRule:PRU01329}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y13115; CAA73575.1; -; mRNA.
DR   EMBL; AB006972; BAB69958.1; -; mRNA.
DR   EMBL; AK302858; BAH13823.1; -; mRNA.
DR   EMBL; AK303399; BAH13953.1; -; mRNA.
DR   EMBL; AK314238; BAG36907.1; -; mRNA.
DR   EMBL; BC036023; AAH36023.1; -; mRNA.
DR   CCDS; CCDS3735.1; -. [O00444-1]
DR   CCDS; CCDS54803.1; -. [O00444-2]
DR   CCDS; CCDS54804.1; -. [O00444-3]
DR   RefSeq; NP_001177728.1; NM_001190799.1. [O00444-2]
DR   RefSeq; NP_001177730.1; NM_001190801.1. [O00444-3]
DR   RefSeq; NP_055079.3; NM_014264.4. [O00444-1]
DR   PDB; 2N19; NMR; -; A=884-970.
DR   PDB; 3COK; X-ray; 2.25 A; A/B=2-275.
DR   PDB; 4JXF; X-ray; 2.40 A; A=4-269.
DR   PDB; 4N7V; X-ray; 2.76 A; A/B=580-808.
DR   PDB; 4N7Z; X-ray; 2.85 A; A=580-808.
DR   PDB; 4N9J; X-ray; 2.60 A; A/B=581-808.
DR   PDB; 4YUR; X-ray; 2.65 A; A=2-275.
DR   PDB; 4YYP; X-ray; 2.60 A; A=884-970.
DR   PDB; 5LHY; X-ray; 3.31 A; 1/2/3/4/5/6/7/8/9/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U=884-970.
DR   PDB; 5LHZ; X-ray; 2.51 A; A/B/C=884-970.
DR   PDB; 6N45; X-ray; 2.64 A; A/B=581-808.
DR   PDB; 6N46; X-ray; 3.71 A; A/B/C/D/E/F/G/H=581-808.
DR   PDB; 6W38; X-ray; 4.48 A; B=585-807.
DR   PDB; 6W3I; X-ray; 3.80 A; B=585-807.
DR   PDB; 6W3J; X-ray; 4.38 A; B=585-807.
DR   PDBsum; 2N19; -.
DR   PDBsum; 3COK; -.
DR   PDBsum; 4JXF; -.
DR   PDBsum; 4N7V; -.
DR   PDBsum; 4N7Z; -.
DR   PDBsum; 4N9J; -.
DR   PDBsum; 4YUR; -.
DR   PDBsum; 4YYP; -.
DR   PDBsum; 5LHY; -.
DR   PDBsum; 5LHZ; -.
DR   PDBsum; 6N45; -.
DR   PDBsum; 6N46; -.
DR   PDBsum; 6W38; -.
DR   PDBsum; 6W3I; -.
DR   PDBsum; 6W3J; -.
DR   AlphaFoldDB; O00444; -.
DR   BMRB; O00444; -.
DR   SMR; O00444; -.
DR   BioGRID; 115956; 135.
DR   ComplexPortal; CPX-1161; CEP192-PLK4 complex.
DR   ComplexPortal; CPX-1299; CEP152-PLK4 complex.
DR   DIP; DIP-34467N; -.
DR   IntAct; O00444; 60.
DR   MINT; O00444; -.
DR   STRING; 9606.ENSP00000270861; -.
DR   BindingDB; O00444; -.
DR   ChEMBL; CHEMBL3788; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O00444; -.
DR   GuidetoPHARMACOLOGY; 2171; -.
DR   iPTMnet; O00444; -.
DR   PhosphoSitePlus; O00444; -.
DR   BioMuta; PLK4; -.
DR   jPOST; O00444; -.
DR   MassIVE; O00444; -.
DR   MaxQB; O00444; -.
DR   PaxDb; O00444; -.
DR   PeptideAtlas; O00444; -.
DR   PRIDE; O00444; -.
DR   ProteomicsDB; 47893; -. [O00444-1]
DR   ProteomicsDB; 47894; -. [O00444-2]
DR   ProteomicsDB; 47895; -. [O00444-3]
DR   Antibodypedia; 26934; 221 antibodies from 34 providers.
DR   DNASU; 10733; -.
DR   Ensembl; ENST00000270861.10; ENSP00000270861.5; ENSG00000142731.11. [O00444-1]
DR   Ensembl; ENST00000513090.5; ENSP00000427554.1; ENSG00000142731.11. [O00444-2]
DR   Ensembl; ENST00000514379.5; ENSP00000423582.1; ENSG00000142731.11. [O00444-3]
DR   GeneID; 10733; -.
DR   KEGG; hsa:10733; -.
DR   MANE-Select; ENST00000270861.10; ENSP00000270861.5; NM_014264.5; NP_055079.3.
DR   UCSC; uc003ifo.4; human. [O00444-1]
DR   CTD; 10733; -.
DR   DisGeNET; 10733; -.
DR   GeneCards; PLK4; -.
DR   HGNC; HGNC:11397; PLK4.
DR   HPA; ENSG00000142731; Group enriched (bone marrow, lymphoid tissue, testis).
DR   MalaCards; PLK4; -.
DR   MIM; 605031; gene.
DR   MIM; 616171; phenotype.
DR   neXtProt; NX_O00444; -.
DR   OpenTargets; ENSG00000142731; -.
DR   Orphanet; 2518; Autosomal recessive chorioretinopathy-microcephaly syndrome.
DR   Orphanet; 808; Seckel syndrome.
DR   PharmGKB; PA36205; -.
DR   VEuPathDB; HostDB:ENSG00000142731; -.
DR   eggNOG; KOG0575; Eukaryota.
DR   GeneTree; ENSGT00940000156316; -.
DR   InParanoid; O00444; -.
DR   OMA; HSSWSEP; -.
DR   OrthoDB; 507604at2759; -.
DR   PhylomeDB; O00444; -.
DR   TreeFam; TF101090; -.
DR   BRENDA; 2.7.11.21; 2681.
DR   PathwayCommons; O00444; -.
DR   Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
DR   Reactome; R-HSA-380259; Loss of Nlp from mitotic centrosomes.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   Reactome; R-HSA-380284; Loss of proteins required for interphase microtubule organization from the centrosome.
DR   Reactome; R-HSA-380320; Recruitment of NuMA to mitotic centrosomes.
DR   Reactome; R-HSA-5620912; Anchoring of the basal body to the plasma membrane.
DR   Reactome; R-HSA-8854518; AURKA Activation by TPX2.
DR   SignaLink; O00444; -.
DR   SIGNOR; O00444; -.
DR   BioGRID-ORCS; 10733; 722 hits in 1120 CRISPR screens.
DR   EvolutionaryTrace; O00444; -.
DR   GeneWiki; PLK4; -.
DR   GenomeRNAi; 10733; -.
DR   Pharos; O00444; Tchem.
DR   PRO; PR:O00444; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; O00444; protein.
DR   Bgee; ENSG00000142731; Expressed in ventricular zone and 122 other tissues.
DR   ExpressionAtlas; O00444; baseline and differential.
DR   Genevisible; O00444; HS.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0032154; C:cleavage furrow; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0098536; C:deuterosome; ISS:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0120098; C:procentriole; IDA:ComplexPortal.
DR   GO; GO:0120099; C:procentriole replication complex; IPI:ComplexPortal.
DR   GO; GO:0000922; C:spindle pole; IBA:GO_Central.
DR   GO; GO:0001741; C:XY body; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007099; P:centriole replication; IDA:ComplexPortal.
DR   GO; GO:0060271; P:cilium assembly; IMP:UniProtKB.
DR   GO; GO:0098535; P:de novo centriole assembly involved in multi-ciliated epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0046601; P:positive regulation of centriole replication; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032465; P:regulation of cytokinesis; IBA:GO_Central.
DR   GO; GO:0060707; P:trophoblast giant cell differentiation; ISS:UniProtKB.
DR   CDD; cd13114; POLO_box_Plk4_1; 1.
DR   CDD; cd13115; POLO_box_Plk4_2; 1.
DR   CDD; cd13116; POLO_box_Plk4_3; 1.
DR   Gene3D; 3.30.1120.120; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033700; Plk4.
DR   InterPro; IPR000959; POLO_box_dom.
DR   InterPro; IPR033699; POLO_box_Plk4_1.
DR   InterPro; IPR033698; POLO_box_Plk4_2.
DR   InterPro; IPR033696; POLO_box_Plk4_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR046437; Ser_Thr-PK_POLO_box_1_sf.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   PANTHER; PTHR24345:SF89; PTHR24345:SF89; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF18190; Plk4_PB1; 1.
DR   Pfam; PF18409; Plk4_PB2; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51984; CPB1; 1.
DR   PROSITE; PS51985; CPB2; 1.
DR   PROSITE; PS50078; POLO_BOX; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cytoplasm;
KW   Cytoskeleton; Dwarfism; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN           1..970
FT                   /note="Serine/threonine-protein kinase PLK4"
FT                   /id="PRO_0000086567"
FT   DOMAIN          12..265
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          586..699
FT                   /note="Cryptic POLO box 1 (CPB1)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01328"
FT   DOMAIN          700..813
FT                   /note="Cryptic POLO box 2 (CPB2)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01329"
FT   DOMAIN          892..956
FT                   /note="POLO box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00154"
FT   REGION          323..458
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          497..538
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          808..828
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        323..359
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        360..376
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        377..396
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        418..457
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        506..532
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        810..828
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        136
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         18..26
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         41
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         45
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:27796307"
FT   MOD_RES         46
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:27796307"
FT   MOD_RES         401
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         665
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         817
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         1..41
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038116"
FT   VAR_SEQ         43..74
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038117"
FT   VARIANT         86
FT                   /note="Y -> C (in dbSNP:rs34156294)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041027"
FT   VARIANT         146
FT                   /note="R -> H (in dbSNP:rs35232579)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041028"
FT   VARIANT         226
FT                   /note="A -> T (in dbSNP:rs35448573)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041029"
FT   VARIANT         232
FT                   /note="S -> T (in dbSNP:rs3811740)"
FT                   /evidence="ECO:0000269|PubMed:11489907,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|Ref.1"
FT                   /id="VAR_019632"
FT   VARIANT         317
FT                   /note="P -> L (in dbSNP:rs35049837)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041030"
FT   VARIANT         449
FT                   /note="N -> D (in dbSNP:rs34906574)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041031"
FT   VARIANT         519
FT                   /note="W -> S (in dbSNP:rs56043017)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041032"
FT   VARIANT         830
FT                   /note="E -> D (in dbSNP:rs17012739)"
FT                   /evidence="ECO:0000269|PubMed:11489907,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|Ref.1"
FT                   /id="VAR_041033"
FT   MUTAGEN         41
FT                   /note="K->M: Abolishes ability to phosphorylate CDC25C and
FT                   CHEK2."
FT                   /evidence="ECO:0000269|PubMed:18239451,
FT                   ECO:0000269|PubMed:19164942"
FT   MUTAGEN         154
FT                   /note="D->A: Catalytically inactive mutant that causes some
FT                   centrosome amplification above background levels when
FT                   overexpressed."
FT                   /evidence="ECO:0000269|PubMed:16244668"
FT   MUTAGEN         170
FT                   /note="T->D: Activating mutant."
FT                   /evidence="ECO:0000269|PubMed:18239451,
FT                   ECO:0000269|PubMed:19164942"
FT   MUTAGEN         669
FT                   /note="N->R: Does not affect the interaction with TENT5C."
FT                   /evidence="ECO:0000269|PubMed:32433990"
FT   MUTAGEN         670
FT                   /note="I->P: Decreases substantially the interaction with
FT                   TENT5C. Does not affect localization to the centrosome.
FT                   Loss of TENT5C recruitment to the centrosome."
FT                   /evidence="ECO:0000269|PubMed:32433990"
FT   CONFLICT        34
FT                   /note="T -> S (in Ref. 2; BAB69958)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="Q -> K (in Ref. 1; CAA73575)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        333
FT                   /note="D -> N (in Ref. 3; BAH13823)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        387
FT                   /note="S -> R (in Ref. 2; BAB69958)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        692
FT                   /note="F -> S (in Ref. 3; BAH13823)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        696
FT                   /note="V -> L (in Ref. 2; BAB69958)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        768
FT                   /note="Y -> F (in Ref. 1; CAA73575)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        842
FT                   /note="A -> D (in Ref. 2; BAB69958)"
FT                   /evidence="ECO:0000305"
FT   HELIX           2..5
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           9..11
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          12..20
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          22..31
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   TURN            32..34
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          37..44
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           45..50
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           54..64
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          75..80
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          82..90
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           97..102
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          104..106
FT                   /evidence="ECO:0007829|PDB:4JXF"
FT   HELIX           110..129
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           139..141
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          142..144
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   STRAND          150..152
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   TURN            158..161
FT                   /evidence="ECO:0007829|PDB:4JXF"
FT   HELIX           193..206
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           217..225
FT                   /evidence="ECO:0007829|PDB:4JXF"
FT   HELIX           236..245
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           250..252
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           256..259
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   TURN            263..265
FT                   /evidence="ECO:0007829|PDB:3COK"
FT   HELIX           587..590
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          602..605
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          607..613
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          619..627
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          630..639
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          645..649
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   HELIX           651..654
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          671..674
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   HELIX           675..677
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   HELIX           680..682
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   HELIX           683..698
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          700..706
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          708..716
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          723..727
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          732..735
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          740..743
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          749..752
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   HELIX           755..759
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   HELIX           765..793
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          800..804
FT                   /evidence="ECO:0007829|PDB:4N9J"
FT   STRAND          887..893
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   TURN            894..896
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   STRAND          897..902
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   STRAND          905..911
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   STRAND          916..922
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   STRAND          924..929
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   TURN            931..933
FT                   /evidence="ECO:0007829|PDB:2N19"
FT   STRAND          935..939
FT                   /evidence="ECO:0007829|PDB:5LHZ"
FT   HELIX           946..961
FT                   /evidence="ECO:0007829|PDB:5LHZ"
SQ   SEQUENCE   970 AA;  108972 MW;  4D56F5FD983211A6 CRC64;
     MATCIGEKIE DFKVGNLLGK GSFAGVYRAE SIHTGLEVAI KMIDKKAMYK AGMVQRVQNE
     VKIHCQLKHP SILELYNYFE DSNYVYLVLE MCHNGEMNRY LKNRVKPFSE NEARHFMHQI
     ITGMLYLHSH GILHRDLTLS NLLLTRNMNI KIADFGLATQ LKMPHEKHYT LCGTPNYISP
     EIATRSAHGL ESDVWSLGCM FYTLLIGRPP FDTDTVKNTL NKVVLADYEM PSFLSIEAKD
     LIHQLLRRNP ADRLSLSSVL DHPFMSRNSS TKSKDLGTVE DSIDSGHATI STAITASSST
     SISGSLFDKR RLLIGQPLPN KMTVFPKNKS STDFSSSGDG NSFYTQWGNQ ETSNSGRGRV
     IQDAEERPHS RYLRRAYSSD RSGTSNSQSQ AKTYTMERCH SAEMLSVSKR SGGGENEERY
     SPTDNNANIF NFFKEKTSSS SGSFERPDNN QALSNHLCPG KTPFPFADPT PQTETVQQWF
     GNLQINAHLR KTTEYDSISP NRDFQGHPDL QKDTSKNAWT DTKVKKNSDA SDNAHSVKQQ
     NTMKYMTALH SKPEIIQQEC VFGSDPLSEQ SKTRGMEPPW GYQNRTLRSI TSPLVAHRLK
     PIRQKTKKAV VSILDSEEVC VELVKEYASQ EYVKEVLQIS SDGNTITIYY PNGGRGFPLA
     DRPPSPTDNI SRYSFDNLPE KYWRKYQYAS RFVQLVRSKS PKITYFTRYA KCILMENSPG
     ADFEVWFYDG VKIHKTEDFI QVIEKTGKSY TLKSESEVNS LKEEIKMYMD HANEGHRICL
     ALESIISEEE RKTRSAPFFP IIIGRKPGST SSPKALSPPP SVDSNYPTRE RASFNRMVMH
     SAASPTQAPI LNPSMVTNEG LGLTTTASGT DISSNSLKDC LPKSAQLLKS VFVKNVGWAT
     QLTSGAVWVQ FNDGSQLVVQ AGVSSISYTS PNGQTTRYGE NEKLPDYIKQ KLQCLSSILL
     MFSNPTPNFH
//
